PROTAC ER Degrader-3
Product Specifications
UNSPSC Description
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab)[1].
Target Antigen
Estrogen Receptor/ERR; PROTACs
Type
Reference compound
Related Pathways
PROTAC;Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/protac-er-degrader-3.html
Solubility
10 mM in DMSO
Smiles
OC1=CC=C(/C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[C@@H](C)[C@H](NC([C@H](C)N(C(OC(C)(C)C)=O)C)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)=C(CC)/C8=CC=CC=C8)C=C1
Molecular Weight
1220.41
References & Citations
[1]Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-128527/PROTAC-ER-Degrader-3-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-128527/
Clinical Information
No Development Reported
CAS Number
2158322-29-1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
